Changes with age previously considered to be "norAdvances in understanding aging processes and mal aging" but that have adverse consequences. Altheir consequences are leading to the development though many age-related changes are asymptomatic of therapies to slow or reverse adverse changes forand are found in many or all persons, they are not necmerly considered to be "normal" aging and proessarily benign. As understanding of adverse effects of cesses that underlie multiple age-related conditions. a "normal" aging change progresses, the change may Estimating the effectiveness of candidate aging therabe recognized as a disease or risk factor. A familiar expies, whose effects on human aging may require ample is osteoporosis, which results in most cases many years to determine, is a particular challenge.
mans. Mammalian intervention studies have been conadverse aging changes by modulating the effects of putative aging mechanisms. There have been reports ducted on the effects of interventions in abnormally short-lived strains with specific conditions or genetic of reduction of age-related declines in cognition by compounds with antioxidant properties (reviewed in defects as well as in long-lived wild-type strains. The latter type of study is widely accepted as preferable for Golden et al. [2002] ). There also have been rodent intervention studies of the effects of agents that modulate studies to examine potential human applicability, and the following discussion is confined to such studies. mitochondrial function on aging changes: acetyl-l-carnitine administration to old rats increased tissue oxyThe rapid discovery rate of findings from very shortlived invertebrates, implicating potential therapeutic gen consumption and mitochondrial membrane potential and reversed age-related declines in cognition and targets for longer-lived species, offers challenges as well as opportunities for mammalian studies: mammaphysical activity (Ames, 2004) . Rodent model systems have limitations for evaluatlian studies of effects on life span and on other responses that require observation over an appreciable ing the likely effect of interventions on humans, because of the considerable differences in age-related percent of the life span require much more time than analogous invertebrate studies. Hence, it is likely that pathologies between rodents and humans. Nonhuman primates have greater similarities, but, other than three the fraction of candidate interventions suggested by invertebrate studies that can actually be tested in mamongoing studies of effects of caloric restriction on aging and life span (Roberts et al., 2001 ), they have not been mals will be quite limited. Expanding mammalian model testing could help to reduce this discrepancy. Strateused in intervention studies of aging therapies. The development of other animal models of human aging pagies to help refine the selection of interventions suggested by in vitro and invertebrate studies for mammathologies may be especially valuable for experimental therapeutic studies. lian testing can also help. For example, it is likely that many factors with positive effects on life span operate Short-or medium-term human studies of intervention effects on factors affecting risk for subsequent on the same or convergent pathways (as has been found for the multiple longevity-related genes that afaging outcomes. When there is sufficient evidence to support human testing of interventions, it is necessary fect the insulin-like peptide signaling pathways), and sorting these factors into a limited number of pathways to decide the age of the population to be studied, the duration of administration of the intervention, and the will facilitate finding the most promising points on these pathways for targeting preclinical and clinical intervenoutcomes to be measured. If the intervention is expected to reverse in older persons adverse aging tions. In addition, more information on functions of homologous proteins in invertebrate models and in mamchanges that increase their risk of clinical outcomes, it may be possible to design a study to measure the efmalian models for therapeutic aging studies could help to distinguish those targets for which mammalian interfect of the intervention on these outcomes directly. The longer the interval needed to observe such an effect, ventions are likely to have positive effects from those that affect pathways that are important in invertebrates the more challenging this task becomes. However, clinical trials with treatment periods of up to 8 years have but not in mammals.
Few mammalian life span studies have tested interbeen successfully organized, and longer trials may be possible. ventions to modulate specific processes implicated in the invertebrate studies discussed above. Antioxidant If, however, the expected effect of the intervention is to decelerate aging changes, requiring that it must be studies have not shown substantial life span effects (Golden et al., 2002), with the exception of moderate initiated relatively early in life and sustained for decades before clinical effects occur, the logistical chalextension in rodents by nitrone free radical spin-trapping agents, though evidence suggests that this is due lenges of conducting a trial long enough to detect these effects are extremely formidable. Except perhaps in to inhibition of specific redox-sensitive signal transduction processes related to inflammation, rather than rethe case of the most promising interventions with abundant preliminary data, alternative designs to determine duction in free radicals per se (Floyd et al., 2002) . In studies of agents affecting mitochondrial function, neishorter-term effects of the intervention can serve as an intermediate step to screen potential interventions for ther α-lipoic acid (which has antioxidant effects) nor coenzyme Q10 (which increases electron transport and longer-term testing. Such studies can be conducted in different age groups to determine age-related differhas antioxidant properties) affected life span in mice (Lee et al., 2004) . ences in response and determine, for example, whether there is a maximum age above which initiating the interAs information on pathways and molecular targets for interventions that may affect longevity accumulates, vention has no effect. These studies can examine effects on known risk the number of promising interventions for mammalian testing will likely increase. Recently, NIA's Interventions factors for clinical outcomes (e.g., bone density and cholesterol), including effects on rates of age-related Testing Program (discussed below) has initiated four mouse intervention studies testing effects on longevity changes in these factors. They can also determine effects on physiologic functions affected by interventions of two anti-inflammatory agents (aspirin and nitroflurbiprofen), 4-hydroxy-phenyl-N-tert-butyl nitrone (a free that delay or reverse aging changes in laboratory animals. In addition, there have been attempts to identify radical scavenger), and nordihydroguarietic acid (a lipoxygenase inhibitor with structural similarities to the "biomarkers of aging" that could predict very long-term consequences of aging therapies in humans, including sirtuin activator resveratrol).
In Figure 1 ): the NIA Longevity Assurance Genes Interactually plays in the aging outcomes being studied. In active Network, involving mainly studies in a wide one specific example, following considerable observarange of laboratory animal models, continues to make tional evidence that oxidized low-density lipoprotein important contributions to identifying possible molecu-(LDL) played a significant role in progression of atherolar targets for interventions (Warner, 2003) . The large sclerosis, a human α-tocopherol intervention study number of genes influencing life span identified by this found that, although α-tocopherol administration innetwork is likely to continue to expand rapidly as highdeed markedly reduced LDL oxidation, it had no effect throughput screening techniques are applied. This research should be useful in identifying or confirmFor interventions in human studies and mammalian ing targets or pathways for intervention. NIA has also models, attention to adverse effects as well as to benebegun a program to develop and screen compounds ficial effects on aging, is crucial. Few interventions have for new drug targets for age-related conditions, presunmitigated benefits; it is unlikely that aging therapies ently focused on neurodegenerative diseases, diabewill be an exception. Though human studies suggest tes, congestive heart failure, and oncologic and immuthat factors contributing to exceptional longevity also nologic diseases. 
Specific Therapies implications of these findings for human aging and for clinical intervention have provoked substantial interest. This section discusses selected examples that illustrate the considerations discussed in preceding sec-
The role of telomeres in regulating the capacity for cell division, and the ability to extend cell division by tions and also illustrate how development of new therapies is stimulated by different types of preliminary intervening to manipulate telomere length and function have been well established. Cultured human cells reach evidence, i.e., by biologic findings implying a cellular structure's role in aging (telomeres), by laboratory anireplicative senescence after cell division in culture and generally express little or no detectable telomerase mal intervention studies (caloric restriction), and by investigations of the consequences of "normal" aging activity by the time that they are approaching senescence. Induction of telomerase activity in normal huchanges (vascular stiffening). to play a critical role in the genesis or promotion of hypertension, atherosclerosis, vascular inflammation, Interventions against Age-Related Vascular Stiffening vascular remodeling, and oxidant stress. In other words, many of the same factors that underlie the ageOne of the most salient age-associated changes in large arteries is an increase in intimal-medial thickness, associated structural and functional alterations of the arterial intima and media are also implicated in the which is accompanied by an increase in stiffness. A growing body of epidemiologic evidence indicates that pathogenesis of clinical arterial disease. These and other factors are the "culprits" that underlie the "risky" these changes, and the ensuing increase in systolic and pulse pressure, formerly thought to be part of "norcomponent of arterial aging in humans (Lakatta, 2003) . As progress is made in further elucidating the diverse mal" aging, precede and predict a higher risk for developing clinical atherosclerosis, hypertension, and myomolecular mechanisms that underlie the arterial alterations that accompany advancing age, novel therapies cardial infarction or stroke (Lakatta and Levy, 2003) . In other words, aging blood vessels provide a milieu in must emerge that will specifically target these pathways and retard or reverse "unsuccessful" 
